Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1933888rdf:typepubmed:Citationlld:pubmed
pubmed-article:1933888lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1933888lifeskim:mentionsumls-concept:C0086661lld:lifeskim
pubmed-article:1933888lifeskim:mentionsumls-concept:C0085983lld:lifeskim
pubmed-article:1933888lifeskim:mentionsumls-concept:C1519554lld:lifeskim
pubmed-article:1933888lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:1933888lifeskim:mentionsumls-concept:C0376669lld:lifeskim
pubmed-article:1933888lifeskim:mentionsumls-concept:C0443199lld:lifeskim
pubmed-article:1933888lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:1933888lifeskim:mentionsumls-concept:C0175668lld:lifeskim
pubmed-article:1933888lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:1933888lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:1933888pubmed:issue23 Pt 1lld:pubmed
pubmed-article:1933888pubmed:dateCreated1991-12-16lld:pubmed
pubmed-article:1933888pubmed:abstractTextIn order to understand the cellular events associated with cell death after the formation of topoisomerase II-DNA cleavable complexes, we compared the induction of endonucleolytic DNA fragmentation by etoposide and its more potent analog, teniposide (VM-26) in the human cell lines HT-29 and HL-60. A new filter-binding assay is described, which allows rapid quantification of nonprotein-linked DNA fragmentation involved in apoptosis. Both cell lines showed similar loss of colony formation ability following 30 min of treatment with various VM-26 concentrations even though the initial topoisomerase II-mediated DNA single-strand break frequency was higher in HL-60 cells. DNA repair studies following drug removal indicated that VM-26-induced DNA breaks reversed rapidly and completely in HT-29 cells, while in HL-60 cells, the initial lesions persisted at and above 5 microM VM-26. In both cell lines, topoisomerase II cleavage complexes, as measured by DNA-protein cross-links by alkaline elution, reversed rapidly and completely within 2-3 h. Secondary DNA fragmentation resembling chromatin endonucleolytic cleavage by apoptosis could be detected in HL-60 cells 3 h after VM-26 or etoposide treatment but not in HT-29 cells. Secondary DNA fragmentation was also induced in the human colon cancer cell lines COLO 320, which have c-myc amplification. Since HL-60 cells also have c-myc amplification and HT-29 do not, it is possible that c-myc overexpression may be involved in secondary DNA fragmentation. Finally, our results indicate heterogeneity of cell death mechanisms after exposure to topoisomerase II inhibitors among human cancer cell lines.lld:pubmed
pubmed-article:1933888pubmed:languageenglld:pubmed
pubmed-article:1933888pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1933888pubmed:citationSubsetIMlld:pubmed
pubmed-article:1933888pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1933888pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1933888pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1933888pubmed:statusMEDLINElld:pubmed
pubmed-article:1933888pubmed:monthDeclld:pubmed
pubmed-article:1933888pubmed:issn0008-5472lld:pubmed
pubmed-article:1933888pubmed:authorpubmed-author:BertrandRRlld:pubmed
pubmed-article:1933888pubmed:authorpubmed-author:PommierYYlld:pubmed
pubmed-article:1933888pubmed:authorpubmed-author:KerriganDDlld:pubmed
pubmed-article:1933888pubmed:authorpubmed-author:SarangMMlld:pubmed
pubmed-article:1933888pubmed:authorpubmed-author:JenkinJJlld:pubmed
pubmed-article:1933888pubmed:issnTypePrintlld:pubmed
pubmed-article:1933888pubmed:day1lld:pubmed
pubmed-article:1933888pubmed:volume51lld:pubmed
pubmed-article:1933888pubmed:geneSymbolc-myclld:pubmed
pubmed-article:1933888pubmed:ownerNLMlld:pubmed
pubmed-article:1933888pubmed:authorsCompleteYlld:pubmed
pubmed-article:1933888pubmed:pagination6280-5lld:pubmed
pubmed-article:1933888pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1933888pubmed:meshHeadingpubmed-meshheading:1933888-...lld:pubmed
pubmed-article:1933888pubmed:meshHeadingpubmed-meshheading:1933888-...lld:pubmed
pubmed-article:1933888pubmed:meshHeadingpubmed-meshheading:1933888-...lld:pubmed
pubmed-article:1933888pubmed:meshHeadingpubmed-meshheading:1933888-...lld:pubmed
pubmed-article:1933888pubmed:meshHeadingpubmed-meshheading:1933888-...lld:pubmed
pubmed-article:1933888pubmed:meshHeadingpubmed-meshheading:1933888-...lld:pubmed
pubmed-article:1933888pubmed:meshHeadingpubmed-meshheading:1933888-...lld:pubmed
pubmed-article:1933888pubmed:meshHeadingpubmed-meshheading:1933888-...lld:pubmed
pubmed-article:1933888pubmed:meshHeadingpubmed-meshheading:1933888-...lld:pubmed
pubmed-article:1933888pubmed:meshHeadingpubmed-meshheading:1933888-...lld:pubmed
pubmed-article:1933888pubmed:meshHeadingpubmed-meshheading:1933888-...lld:pubmed
pubmed-article:1933888pubmed:meshHeadingpubmed-meshheading:1933888-...lld:pubmed
pubmed-article:1933888pubmed:meshHeadingpubmed-meshheading:1933888-...lld:pubmed
pubmed-article:1933888pubmed:year1991lld:pubmed
pubmed-article:1933888pubmed:articleTitleDifferential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.lld:pubmed
pubmed-article:1933888pubmed:affiliationLaboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.lld:pubmed
pubmed-article:1933888pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1933888pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1933888lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1933888lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1933888lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1933888lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1933888lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1933888lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1933888lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1933888lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1933888lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1933888lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1933888lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1933888lld:pubmed